Meridian Bioscience Corrects Prior Update Regarding Revogene® SARS-CoV-2 EUA Withdrawal
CINCINNATI, Feb. 23, 2021 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, updated its communication regarding the withdrawal of its application for Emergency Use Authorization (EUA) with the U.S. Food and Drug Administration (FDA) for the SARS-CoV-2 molecular diagnostic test on its Revogene® platform. In […]
Meridian Bioscience Provides a Further Update on the Revogene® SARS-CoV-2 EUA Submission
CINCINNATI, Feb. 23, 2021 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, provided a further update on its application for Emergency Use Authorization (EUA) with the U.S. Food and Drug Administration (FDA) for the SARS-CoV-2 molecular diagnostic test on its Revogene® platform. Following the submission […]